MBXBF
Price
$0.17
Change
-$0.00 (-0.00%)
Updated
Sep 4 closing price
Capitalization
23.31M
NBY
Price
$2.72
Change
-$1.01 (-27.08%)
Updated
Sep 8, 04:59 PM (EDT)
Capitalization
15.72M
Interact to see
Advertisement

MBXBF vs NBY

Header iconMBXBF vs NBY Comparison
Open Charts MBXBF vs NBYBanner chart's image
Microbix Biosystems
Price$0.17
Change-$0.00 (-0.00%)
Volume$1.26M
Capitalization23.31M
NovaBay Pharmaceuticals
Price$2.72
Change-$1.01 (-27.08%)
Volume$48.2K
Capitalization15.72M
MBXBF vs NBY Comparison Chart in %
Loading...
MBXBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MBXBF vs. NBY commentary
Sep 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBXBF is a Hold and NBY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 09, 2025
Stock price -- (MBXBF: $0.17 vs. NBY: $3.73)
Brand notoriety: MBXBF and NBY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MBXBF: 953% vs. NBY: 105%
Market capitalization -- MBXBF: $23.86M vs. NBY: $21.72M
MBXBF [@Biotechnology] is valued at $23.86M. NBY’s [@Biotechnology] market capitalization is $21.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MBXBF’s FA Score shows that 1 FA rating(s) are green whileNBY’s FA Score has 2 green FA rating(s).

  • MBXBF’s FA Score: 1 green, 4 red.
  • NBY’s FA Score: 2 green, 3 red.
According to our system of comparison, NBY is a better buy in the long-term than MBXBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MBXBF’s TA Score shows that 4 TA indicator(s) are bullish while NBY’s TA Score has 5 bullish TA indicator(s).

  • MBXBF’s TA Score: 4 bullish, 2 bearish.
  • NBY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MBXBF is a better buy in the short-term than NBY.

Price Growth

MBXBF (@Biotechnology) experienced а -4.24% price change this week, while NBY (@Biotechnology) price change was +109.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was +11.00%, and the average quarterly price growth was +33.00%.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MBXBF($23.3M) has a higher market cap than NBY($15.7M). MBXBF has higher P/E ratio than NBY: MBXBF (22.17) vs NBY (1.17). NBY YTD gains are higher at: 520.632 vs. MBXBF (-42.907). MBXBF has higher annual earnings (EBITDA): 2.47M vs. NBY (-7.05M). MBXBF has more cash in the bank: 12.1M vs. NBY (5.34M). NBY has less debt than MBXBF: NBY (1.04M) vs MBXBF (6.41M). MBXBF has higher revenues than NBY: MBXBF (21.1M) vs NBY (9.78M).
MBXBFNBYMBXBF / NBY
Capitalization23.3M15.7M148%
EBITDA2.47M-7.05M-35%
Gain YTD-42.907520.632-8%
P/E Ratio22.171.171,889%
Revenue21.1M9.78M216%
Total Cash12.1M5.34M226%
Total Debt6.41M1.04M615%
FUNDAMENTALS RATINGS
MBXBF vs NBY: Fundamental Ratings
MBXBF
NBY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8412
PRICE GROWTH RATING
1..100
9234
P/E GROWTH RATING
1..100
81
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (45) in the Biotechnology industry is in the same range as MBXBF (73) in the null industry. This means that NBY’s stock grew similarly to MBXBF’s over the last 12 months.

NBY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MBXBF (100) in the null industry. This means that NBY’s stock grew similarly to MBXBF’s over the last 12 months.

NBY's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for MBXBF (84) in the null industry. This means that NBY’s stock grew significantly faster than MBXBF’s over the last 12 months.

NBY's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for MBXBF (92) in the null industry. This means that NBY’s stock grew somewhat faster than MBXBF’s over the last 12 months.

NBY's P/E Growth Rating (1) in the Biotechnology industry is in the same range as MBXBF (8) in the null industry. This means that NBY’s stock grew similarly to MBXBF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MBXBFNBY
RSI
ODDS (%)
Bullish Trend 4 days ago
53%
Bearish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
65%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 4 days ago
83%
MACD
ODDS (%)
Bullish Trend 4 days ago
64%
Bullish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
84%
Advances
ODDS (%)
N/A
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
Bearish Trend 7 days ago
71%
Bearish Trend 14 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
54%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
73%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
MBXBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CTXR1.230.08
+6.96%
Citius Pharmaceuticals Inc
ARGX750.7817.12
+2.33%
argenx SE
SPT15.150.29
+1.95%
Sprout Social
CBT81.050.03
+0.04%
Cabot Corp
TCX17.83-0.15
-0.83%
Tucows

MBXBF and

Correlation & Price change

A.I.dvisor tells us that MBXBF and CRMD have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MBXBF and CRMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBXBF
1D Price
Change %
MBXBF100%
N/A
CRMD - MBXBF
27%
Poorly correlated
-3.13%
TECX - MBXBF
23%
Poorly correlated
-2.72%
BVNKF - MBXBF
21%
Poorly correlated
N/A
NBY - MBXBF
20%
Poorly correlated
-11.61%
MMIRF - MBXBF
15%
Poorly correlated
N/A
More

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been loosely correlated with THAR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NBY jumps, then THAR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
-11.61%
THAR - NBY
45%
Loosely correlated
-7.77%
NEVPF - NBY
41%
Loosely correlated
N/A
ATON - NBY
38%
Loosely correlated
-6.61%
ALT - NBY
30%
Poorly correlated
+6.18%
ORMP - NBY
29%
Poorly correlated
+0.45%
More